HomeAI · summaries
Storia in 6 fonti
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain - Ionis Pharmaceuticals (NASDAQ:IONS)
Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
AstraZeneca, Ionis drug fails big heart disease study in major setback
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and…
- ·
endpoints.news
AstraZeneca sinks on unexpected heart drug trial failure
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.
